Eventide Asset Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
|
|||||
|
2024
Q4 | $13.6M | Sell |
|
|||||
|
2024
Q3 | $31.5M | Hold |
|
|||||
|
2024
Q2 | $35M | Sell |
|
|||||
|
2024
Q1 | $182M | Buy |
|
|||||
|
2023
Q4 | $175M | Buy |
|
|||||
|
2023
Q3 | $157M | Buy |
|
|||||
|
2023
Q2 | $194M | Buy |
|
|||||
|
2023
Q1 | $55.5M | Buy |
|
|||||
|
2022
Q4 | $43.4M | Buy |
|
|||||
|
2022
Q3 | $40.3M | Buy |
|
|||||
|
2022
Q2 | $28.2M | Buy |
|
|||||
|
2022
Q1 | $35.1M | Buy |
|
|||||
|
2021
Q4 | $44.5M | Hold |
|
|||||
|
2021
Q3 | $35.3M | Buy |
|
|||||
|
2021
Q2 | $22.4M | Sell |
|
|||||
|
2021
Q1 | $36.1M | Hold |
|
|||||
|
2020
Q4 | $43.2M | Sell |
|
|||||
|
2020
Q3 | $28.8M | Sell |
|
|||||
|
2020
Q2 | $42.5M | Buy |
|